<DOC>
	<DOC>NCT00224133</DOC>
	<brief_summary>A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.</brief_summary>
	<brief_title>The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months</brief_title>
	<detailed_description>This will be a multi-center, open-label 40 week investigation in up to 1,200 men with signs and symptoms of benign prostatic hyperplasia. The following procedures are utilized: physical exams, electrocardiograms, clinical laboratory tests, vital signs, the International Prostate Symptom Score, maximum urine flow rate, adverse events, concomitant medications, and compliance. All subjects had previously participated in a 12-week double-blind placebo controlled trial (NCT000224107 or NCT000224120)</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Silodosin</mesh_term>
	<criteria>Males in good general health and at least 50 years of age, who have completed SI04009 or SI04010. Medical conditions that would confound the efficacy evaluation. Medical conditions in which it would be unsafe to use an alphablocker. The use of concomitant drugs that would confound the efficacy evaluation. The use of concomitant drugs that would be unsafe with this alphablocker.</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>benign prostatic hyperplasia, alpha blocker</keyword>
</DOC>